Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Terminal state08.01.03.0790.001859%-
Neck mass15.03.02.0070.001239%-
Hepatic siderosis09.01.10.008; 14.13.03.0050.004585%-
Acute chest syndrome01.04.02.004; 22.06.03.004; 24.03.08.0060.006815%-
Leukaemic infiltration pulmonary01.10.03.007; 16.01.03.007; 22.08.01.0160.001239%-
Growth hormone deficiency05.03.02.0040.001239%-
Hepatic mass09.01.08.0150.001239%-
Cell death08.03.03.003; 14.11.02.0050.001239%-
Nephrogenic anaemia01.03.04.001; 20.01.01.0070.001239%-
Carnitine deficiency14.08.04.0220.001239%-
Leukaemia recurrent01.10.03.005; 16.01.03.005---
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.001859%-
Graft versus host disease in liver09.01.07.033; 10.02.01.060; 12.02.09.0290.001239%-
Apparent death08.01.03.0620.001859%-
Oncologic complication16.32.03.0250.001239%-
Pure white cell aplasia01.03.03.0130.001239%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.004337%-
Eye colour change06.06.06.0080.002726%-
Internal haemorrhage24.07.01.0720.001859%-
Primary myelofibrosis01.13.03.008; 16.21.03.0080.001239%-
Alloimmunisation01.06.01.006; 10.02.04.003; 18.04.18.0020.001239%-
Bone marrow transplant rejection01.05.01.023; 10.02.03.0080.001239%-
Cardiac iron overload02.04.01.014; 12.02.08.009; 14.13.03.0080.005204%-
Dilated cardiomyopathy02.04.01.0170.001239%-
Disease complication08.01.03.0870.006815%-
Gait inability08.01.02.011; 17.02.05.0690.010532%-
Hepatic cytolysis09.01.07.0360.001239%-
Hernia perforation08.01.04.0060.001239%-
Hypersensitivity myocarditis02.04.03.006; 10.01.03.0550.002478%-
Illness08.01.03.091---
The 17th Page    First    Pre   17 18    Next   Last    Total 18 Pages